The GLP is committed to full transparency. Download and review our 2019 Annual Report

Inside the quest to use gene therapy to cure a form of congenital blindness

[I]nherited retinal disease affects thousands of people around the world—people who are born with poor vision and then slowly lose their sight over time. Often, they are only able to see the shape of an object, and only in bright sunlight. Our work uses gene therapy to deliver a normal copy of that disease-causing gene to help restore vision.

Thinking back, we were lucky to have been so naive when we began this work, because if we had known in advance about the dozens of challenges that were to come, including developing and validating a novel endpoint, coming up with a rigorous trial design for an ultrarare disease population, bringing manufacturing to commercial standards, and building a database of the natural history of this disease, we may never have started.

Related article:  Viewpoint: AI may boost our diagnostic abilities, but it's not ready to replace human doctors

Spark Therapeutics submitted more than 65,000 pages of documentation to the U.S. Food and Drug Administration (FDA) and went through a full day of questioning by their advisory committee.

And of course, our journey to help patients and families living with RPE65 gene mutations is not over. We continue to look for ways to make genetic screening for inherited retinal diseases a standard practice.

Read full, original post: How Gene Therapy Can Reverse a Form of Congenital Blindness

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend